Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

The Motley Fool

14 Jun 2026, 20:56 UTC · 3h ago

A Capri Holdings Director Sold His Entire Stake in the Company. Here's a Deeper Look at the Stock Transaction.

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

A Capri Holdings Director Sold His Entire Stake in the Company. Here's a Deeper Look at the Stock Transaction.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Capri Holdings Director Stephen F. Reitman completely liquidated his holdings in the company via the sale of 17,981 shares. — Full liquidation by an insider often signals a lack of confidence in the company's future growth or valuation.
-0.60
2
Capri Holdings reported a significant financial turnaround, moving from a $1.2 billion net loss in fiscal 2025 to a net income of $138 million in fiscal 2026. — A swing from massive losses to profitability is a strong positive fundamental signal, though here it was aided by a brand sale.
+0.50
3
The company sold its Versace brand in 2025 to address flagging performance. — Selling a core luxury brand indicates a shrinking portfolio and an admission of failure to maintain that specific asset.
-0.30
4

6 related stories

The Motley Fool
18h ago
Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?
- insider selling
- revenue growth
- sec filing
Read

A Capri Holdings Director… — CPRI -0.20 | NewsImpactScreener

A Capri Holdings Director Sold His Entire Stake in the Company. Here's a Deeper Look at the Stock Transaction.

What matters in this story

Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?

A Capri Holdings Director Sold His Entire Stake in the Company. Here's a Deeper Look at the Stock Transaction.

What matters in this story

Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

EverCommerce's CEO Sells 19,200 Shares

Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?

Axcelis VP Corporate Controller Sells 2,574 Shares — Is ACLS Still Worth Buying?

A Warby Parker Director Sold 10,000 Company Shares. Here's a Deeper Look at the Transaction.

A Capri Holdings Director Sold His Entire Stake in the Company. Here's a Deeper Look at the Stock Transaction.

What matters in this story

Next reads from the same story arc

Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?

A Capri Holdings Director Sold His Entire Stake in the Company. Here's a Deeper Look at the Stock Transaction.

What matters in this story

Next reads from the same story arc

Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

EverCommerce's CEO Sells 19,200 Shares

Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?

Axcelis VP Corporate Controller Sells 2,574 Shares — Is ACLS Still Worth Buying?

A Warby Parker Director Sold 10,000 Company Shares. Here's a Deeper Look at the Transaction.